A5009543853- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Malaria Research and Control
- Health Systems, Economic Evaluations, Quality of Life
- Chronic Myeloid Leukemia Treatments
- Mosquito-borne diseases and control
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- Statistical Methods in Clinical Trials
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Economic and Financial Impacts of Cancer
- Drug Transport and Resistance Mechanisms
- Advanced Breast Cancer Therapies
- Gastric Cancer Management and Outcomes
- Gastrointestinal Tumor Research and Treatment
- Biomedical Ethics and Regulation
- Renal cell carcinoma treatment
- Protein Degradation and Inhibitors
- Ethics in Clinical Research
GlycoMimetics (United States)
2024
MacroGenics (United States)
2019-2022
Otsuka (United States)
2010-2019
Pharmaceutical Product Development (United States)
2014-2019
Georgetown University
2019
Seoul National University Hospital
2019
Sarah Cannon
2019
Astex Pharmaceuticals
2017-2018
Otsuka Pharmaceutical (Spain)
2012-2016
Princeton University
2015
In both immunoglobulins (Ig) and T cell receptors (TCR), the rearrangement of V, D, J region sequence elements during lymphocyte maturation creates an enormous degree diversity in area referred to as complementarity determining 3 (CDR3) loop. Variations particular used, precise points recombination, random nucleotide addition all lead extensive length heterogeneity. CDR3 loops are often critical for antigen binding Igs appear provide principal peptide residues TCRs. To better understand...
ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity trastuzumab but incorporates an engineered Fc region to increase immune activation.To compare the clinical efficacy vs trastuzumab, each chemotherapy, patients pretreated ERBB2-positive ABC.The SOPHIA phase 3 randomized open-label trial plus chemotherapy enrolled 536 from August 26,...
On January 26, 2006, sunitinib (Sutent) received regular approval as monotherapy for the treatment of patients with gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate (Gleevec). Time-to-tumor (TTP) sunitinib-treated was superior that placebo-treated patients. Median TTP 27.3 weeks, compared 6.4 weeks (p < .0001). Partial responses were observed in 6.8% and no Sunitinib also accelerated advanced renal cell carcinoma (RCC). In two single-arm trials...
Four non-small-cell lung cancer (NSCLC) registration trials were utilized to develop models linking survival risk factors and changes in tumor size during treatment. The purpose was leverage existing quantitative knowledge facilitate future development of anti-NSCLC drugs. Eleven screened using a Cox model. A mixed exponential decay linear growth model for modeling size. Survival times described parametric Eastern Cooperative Oncology Group (ECOG) score baseline consistent prognostic...
SUMMARY Plasmodium falciparum-infected erythrocytes (IRBC) synthesize 3 histidine-rich proteins: HRP-I or the knob-associated HRP, HRP-II and HRP-III SHARP. In order to distinguish these proteins immunochemically we prepared monoclonal antibodies which react with HRP-I, HRP-III, rabbit antisera against synthetic peptides derived from sequences. A comparative analysis of diverse P. falciparum parasites was made using immunoprecipitation Western blotting. (M r 80000–115000) identified in all...
1000 Background: Pretreated HER2+ MBC lacks a defined standard of care, although T is commonly used. M has similar HER2 binding and antiproliferative effects as T. By contrast, M’s Fc region engineered to increase affinity for both alleles the activating receptor (FcR), CD16A, decrease inhibitory FcR, CD32B. The low CD16A-158F allele (~85% population) been associated with diminished clinical response In Phase 1 trial, demonstrated acceptable safety, anti-tumor activity, evidence...
While recent evidence strongly suggests that the third complementarity determining regions (CDR3s) of T cell receptors (TCRs) directly contact antigenic peptides bound to major histocompatibility complex (MHC) molecules, nature other TCR contact(s) is less clear. Here we probe extent which different antigens can affect this interaction by comparing responses cells bearing structurally related TCRs cytochrome c and staphylococcal enterotoxin A (SEA) presented 13 mutant antigen-presenting...
Abstract Lessons Learned OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation that exhibited promising anticancer activity in preclinical models. In this first-in-human phase I study unselected advanced cancers, treatment-emergent adverse events, most frequently nausea, fatigue, vomiting, were generally mild to moderate intensity could be medically managed. Overall, only modest clinical was observed after given as monotherapy. Notable antitumor seen subject...
We have used multiple-amino acid replacement mutagenesis to examine the roles of TCR homologues Ig complementarity-determining regions (CDR) and framework sequences in Ag-MHC Staphylococcus aureus enterotoxin reactivity. In three cases examined, transplantation CDR3 between I-Ek-restricted that recognize distinct peptides did not result transfer peptide Thus structural context loops, e.g., both neighboring CDR V beta structure, must play a crucial, albeit supporting, role ligand recognition....
Abstract Background: Human epidermal growth factor receptor 2 (HER2)-targeting monoclonal antibodies (mAb) are the standard of care in early-to-advanced HER2+ breast cancer. However, for relapsed/refractory disease, limited options exist after progression on trastuzumab (T), pertuzumab (P), and ado-trastuzumab emtansine. Margetuximab (M) is an Fc-engineered anti-HER2 mAb that targets same epitope as T exerts similar antiproliferative effects. Compared with T, M has higher affinity both 158V...
Abstract Background Patient survival in advanced/metastatic melanoma, non‐small cell lung cancer (NSCLC), and renal carcinoma (RCC) has improved with immune checkpoint inhibitors (ICI). Biomarkers' role prognosis treatment been limited by conflicting trial results. Methods This retrospective, observational study analyzed baseline demographic, clinical, laboratory, data versus outcomes of The US Oncology Network adult outpatients. Patients NSCLC, or RCC treated between January 1, 2015...
Selectins are cell adhesion proteins discovered in the 1980s. As C-type lectins, selectins contain an essential calcium ion ligand-binding pocket and recognize isomeric tetrasaccharides sialyl Lewis